FDA advisory panels: 40% of patient reps tied to pharma-funded groups

An analysis of FDA advisory committee meetings from 2006-2026 found that nearly 40% included a patient or consumer representative with active ties to a pharma-funded advocacy group. This raises conflict-of-interest concerns about the independence of patient voices in regulatory decisions. The finding is based on a STAT News analysis and is not yet independently corroborated.